Table 1.
Patient and graft demographics of 63 vaccinated double unit CBT recipients.
| Characteristic | Value |
|---|---|
|
| |
| Age (median, range) | 34 years (0.9–64) |
|
| |
| Diagnosis (N, %) | |
| AML (CR1–3) | 31 (49%) |
| ALL (CR1–4) | 11 (17%) |
| MDS/CML | 3 (5%) |
| Lymphoma | 18 (29%) |
|
| |
| Conditioning (N) | |
| High dose: | |
| Cy/Flu/TBI 1320–1375 | 26 |
| Thio/Flu/TBI 1320 | 1 |
| Clo/Mel/Thio | 5 |
| Intermediate: | |
| Cy/Flu/Thio/TBI 400 | 17 |
| Reduced intensity: | |
| Mel/Flu | 3 |
| Non-myeloablative: | |
| Cy/Flu/TBI 200 | 11 |
|
| |
| Engrafting units (median, range) | |
| 8 HLA-allele match* | 5/8 (2–7) |
| Infused TNC × 107/kg | 2.1 (1.2–11.3) |
| Infused CD34+ × 105/kg | 0.8 (0.1–4.1) |
|
| |
| Pre-vaccination rituximab, (N, %) | 13 (21%) |
|
| |
| GVHD (N, %) | |
| Grade II–IV acute (grade) | 38 (60%)** |
| Chronic | 10 (16%)*** |
|
| |
| Vaccinated on immunosuppression (N, %) | |
| No | 45 (71%) |
| Yes | 18 (29%) |
|
| |
| Pre-vaccine immune recovery Median (Range) | |
| CD4+ | 577/μl (range 190–2,296) |
| CD4+ CD45RA+ | 127/μl (range 14–1,856) |
| CD19+ | 793/μl (range 0–5,533) |
| IgG | 786 mg/dl (range 502–2,965) |
*
Donor recipient HLA-match;
**
27 II, 10 III, 1 IV;
***
9 mild, 1 severe (Prior acute: 6 yes, 4 no)
AML, Acute Myeloid Leukemia; ALL, Acute Lymphoblastic Leukemia; MDS, Myelodysplastic Syndrome; CML, Chronic Myelogenous Leukemia; Cy, Cyclophosphamide; Flu, Fludarabine; TBI, Total Body Irradiation; Thio, Thiotepa; Clo, Clofarabine; Mel, Melphalan; HLA; Human Leukocyte Antigen; TNC, Total Nucleated Cell Count; GVHD, Graft-verus-Host Disease